KR20080011458A - Functional foods and compositions thereof that reduce cholesterol and improve cardiovascular disease - Google Patents

Abstract

The present invention relates to foods having a cholesterol-lowering effect and a cardiovascular disease-improving effect, and more particularly, a food containing the extracts of Astragalus, green tea, brown root, soybean, and Cultivator as a main component, which has a cholesterol-lowering effect and a cardiovascular disease-improving effect. It relates to food and compositions thereof.

Description

   Functional food and its composition improving cardiovascular disease and reducing cholesterol

The present invention relates to foods having a cholesterol-lowering effect and a cardiovascular disease-improving effect, and more particularly, a food containing the extracts of Astragalus, green tea, brown root, soybean, and Cultivator as a main component, which has a cholesterol-lowering effect and a cardiovascular disease-improving effect. It relates to food and compositions thereof.

As economic and social changes occur, various economic and social changes occur, and dietary and lifestyle changes gradually, and the incidence of different types of adult diseases is significantly increased. In particular, backward diseases such as infectious diseases, digestive and respiratory diseases gradually decrease, and hypercholesterolemia, hyperlipidemia, hypertension, arteriosclerosis, which are cardiovascular diseases caused by aging population, overeating, drinking, smoking, lack of exercise, and obesity. The same chronic disease is increasing.

Cardiovascular disease is a chronic disease caused by the oxidation of LDL cholesterol in the serum cholesterol and accumulation of oxidized products in the subcutaneous tissue in the arteries and the increase of various inflammatory reactions. It is the second leading cause of death among the elderly in Korea. . In particular, cardiovascular diseases such as hyperlipidemia, hypertension, hypertensive retinopathy, arrhythmia, myocardial infarction, deep vein and angina pectoris, and cardiac infarction account for the majority of elderly deaths (Korean Patent No. 10-0667038).

   According to the hyperlipidemia diagnosis guideline according to the blood lipid and lipoprotein concentration, normal cholesterol level is 110 ~ 240mg / dl, LDL cholesterol 65 ~ 160mg / dl, triglyceride 200mg / dl or less, which is considered hyperlipidemia. If left untreated, it can lead to serious complications such as hypertension, coronary atherosclerosis (angina, myocardial infarction), and cerebral atherosclerosis (cerebral infarction) (Hyperlipidemia Guidelines for Treatment of Hyperlipidemia).

   Cholesterol is a series of compounds collectively called sterols and is a representative sterol in animals. Endogenous cholesterol is biosynthesized from acetyl-CoA in the liver, adrenal gland, and genital organs. Exogenous cholesterol is absorbed into the small intestine through food.

   In women, postmenopausal dysfunction due to ovarian obstruction reduces estrogen synthesis and secretion and increases the gonadotropin levels secreted by the pituitary gland, thereby increasing the risk of cardiovascular disease (Korean Med Sci 17: 307,2002). Recent reports have shown that estrogens reduce LDL cholesterol by inducing LDL receptors. After menopause, LDL cholesterol is increased due to estrogen deficiency (J Nutr 128: 954, 1998). In addition, postmenopausal hormone deficiency causes increased abdominal fat, which has been reported to increase the risk of ischemic heart disease or hyperlipidemia (J Intern Med 241: 363- 372, 1997; N Engl J Med 342: 427, 1999). In adults, both males and females have increased plasma lipid concentrations with age, and males are higher than women before menopause, but higher in women after menopause, and the incidence of cardiovascular disease is increased by five times, similar to men.

   Postmenopausal hyperlipidemia generally involves diet or drug therapy that limits calorie or animal fat intake, and treatment with estrogen to improve blood lipids is known to be effective, but only 35-40% of estrogens are effective. Alternative therapies are used, and even most of them avoid continuing to use them (Ann. Intern. Med. 1999, 130, 545p-553p). The main reason for this is the rejection and side effects of unnatural estrogen therapy itself, which is based on artificial hormone administration, and many studies have shown that the risk of developing uterine bleeding, stroke, heart attack, breast cancer, and uterine cancer can be increased. (Obstet. Gynecol. 1998, 91, 678p-684p; New Engl. J. Med. 1995, 332, 1589p-1593p).

  Because of these problems, there is increasing interest in replacing estrogen therapy with natural methods of ingesting foods or additives (Am. J. Clin. Nutr. 1998, 68, 1333p-1346p). In particular, phytoestrogen present in plants has almost no side effects and has been reported to reduce the incidence of cancer (J. Clin. Endocrinol. Metab. 1998, 83, 297p-303p).

   Phytoestrogens come in three main forms: isoflavones, coumestans, and lignans. There are about 1000 types of isoflavones, of which genistein and daidzein are the most widely known, and are believed to have estrogen activity (Arch. Int. Med. 2001, 16, 1161p). -1171p). Various isoflavones, including the lipid-inhibiting effects of isoflavones (Art Thr Vas Bio 17: 2524, 1997; J Nutr 129: 1585, 1999) and lowering blood LDL levels (Kirk EA et al., J Nutr 128: 954, 1998) Their estrogen activity varies widely, and the most biologically active forms are not yet known exactly (Arch. Int. Med. 2001, 16, 1161p-1171p).

    On the other hand, highly oxidized LDL (Oxidized LDL) accumulated on the inner wall of blood vessels accumulates in the blood vessels as cholesterol and cholesteryl esters, forming foam cells, which causes atherosclerosis. Polyphenols have been reported to decrease LDL cholesterol and triglyceride levels in the blood, while increasing HDL cholesterol, which is known to be due to the high antioxidant effects that prevent the oxidation of LDL, which causes atherosclerosis. Patent 10-0376942).

    Green tea, anti-obesity green tea manufacturing method patent (Korean Patent No. 10-0376942), Habaek, Guruin, which is composed mainly of lotus root, Donggyuja, crust, red sesame, Jinho-ro, super-determinate, taeksa, rhubarb, corn beard and mountain cultivation Patents including various Chinese herbal medicines are disclosed, including patents for the prevention and treatment of hyperlipidemia and angina pneumonia, including Angelica, Angelica sinensis, Ginseng, turmeric, Red Peony, and half of the herb (Korean Patent No. 10-0374416). The effect is weak (Korean Patent No. 10-0499384), and it cannot be used in food by including raw materials not listed in the Food Code (published by the Korea Food Industry Association).

    Therefore, an object of the present invention is to solve the above problems can replace the herbal medicine that can not be used as food, to prevent side effects due to hormone replacement therapy, to provide a functional food with a safe and high cardiovascular disease improvement effect.

    Another object of the present invention provides a composition for producing a food of the above object.

    In order to achieve the above object, the present invention aims to provide a food having an effect of reducing cholesterol and improving cardiovascular disease, which is mainly composed of Astragalus, green tea, brown root, soybean, and C. aureus extract.

   Hwanggi, a legume, is a patent for a liver function improver containing isoflavones. There has been no report of direct cardiovascular improvement, and there are no cases of defects.

   According to the present invention, it was found that the mixed composition of Astragalus, green tea, brown root, soybean, and deficiency extract shows high cholesterol reduction and cardiovascular disease improvement. This is a representative ingredient of known isoflavones, genistein and diidzein. It is proved experimentally as derived from synergistic effect by the action of 1000 kinds of isoflavone components including) and various polyphenol components including catechin.

   According to the present invention by developing a food having a cholesterol-lowering effect containing the main ingredient of Astragalus, brown root, deficiency, soybean, green tea extract, it is possible to replace the herbal medicine that can not be used as a food, to prevent side effects due to hormone replacement therapy, It is possible to provide a functional food having a safe and high cardiovascular disease improvement effect.

   In the present invention, after extracting hot water, brown root, and the deficiency hot water at 90 ~ 100 ℃, it is mixed with green tea extract, soybean powder. Astragalus, green tea, brown root, soybean, the weight ratio of the extract is 0.1 ~ 0: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10: 0.1 ~ 10, preferably 0.5 ~ 5: 0.5 ~ 5: 0.5 ~ 5: 0.5-5: 0.5-5, More preferably, it is 2: 4: 1: 12.5: 0.5.

   According to the present invention can be prepared functional foods containing extracts that are expected to reduce cholesterol and improve cardiovascular diseases by preparing a mixture powder of Astragalus, green tea, brown root, soybean, Cultivator extract.

  Hereinafter, the present invention will be described in detail through non-limiting examples.

  Example 1 Preparation of Mixed Powder

 After washing 5kg of Astragalus, 3kg of brown root, and 3kg of Clarifier, 5L of water was added and hot water was extracted at 90-100 ° C for 5 hours. The extract was filtered through a 200 mesh filter cloth, concentrated under a reduced pressure concentrator, and hot-air dried to obtain 2 kg, 1 kg, and 500 g of powder, respectively. The powder was mixed with 2.5 kg and 4 kg of green tea extract and soybean powder containing 30% of green tea catechin purified by adsorption on a resin (big pore resin) to prepare a mixed powder.

   Example 2 Cholesterol Reduction Preventive Effect in Animals

  Six-month-old SD female rats were divided into five groups from A to E, and eight animals were prepared for each group. A group (Normal group) was fed with a solid food and a B-E group with 30% by weight of animal fat was fed for 30 days. . At this time, the group C purchased Cheonggan-tang used in the treatment of hyperlipidemia at the pharmacy and administered 200mg / kg per day for 30 days, and the green tea extract and the mixed powder prepared in Example 1 were mixed with the group C and the group D and E, respectively. It was administered in the same way. After 30 days of blood collection, plasma was separated and analyzed using an analysis kit to analyze LDL cholesterol, HDL cholesterol, and total cholesterol content.

  As shown in Table 1, the total powder reduction effect including LDL cholesterol was most pronounced in the mixed powder than the green tea extract, and this is due to the synergic effect of the mixed powder, which is higher than the herbal extract Cheonggan-tang. High. It can be seen that the mixed powder has a high cardiovascular disease prevention effect through cholesterol reduction.

<Table 1> Changes in Lipid Content in Blood

                                             (Unit: mg / dl)

Total cholesterol LDL HDL A Normal 275 145 135 B Control 433 288 138 C Cheongantang 338 201 144 D Green Tea Extract 345 205 143 E Mixed powder 299 160 148

Example 3 Cholesterol Reduction Therapeutic Effect in Animals

  Six-month-old SD female rats were divided into five groups from A to E, and eight animals were prepared for each group. A group (Normal group) was fed with a solid food and a B-E group with 30% by weight of animal fat was fed for 30 days. . After 30 days, C was purchased from the drugstore Cheonggan-tang used for the treatment of hyperlipidemia at a pharmacy for 30 days at 200mg / kg, and the green tea extract and the mixed powder prepared in Example 1 were added to the D and E groups, respectively. LDL cholesterol, HDL cholesterol, and total cholesterol contents were analyzed by using an analysis kit, and then plasma was separated by administration in the same manner as the group.

  As shown in Table 2, the total powder reduction effect including LDL cholesterol was most prominent in the mixed powder than the green tea extract, which is due to the synergic effect of the mixed powder, which is more effective than the herbal extract Cheongan-tang. High. It can be seen that the mixed powder has a high cardiovascular disease treatment effect by reducing cholesterol.

 <Table 2> Changes in Lipid Content in Blood

                                            (Unit: mg / dl)

Total cholesterol LDL HDL A Normal 275 145 135 B Control 433 288 138 C Cheongantang 348 210 145 D Green Tea Extract 355 213 145 E Mixed powder 305 175 146

Example 4 Tablet Preparation

  98% by weight of the mixed powder of Example 1, 1% by weight of silicon dioxide, 1% by weight of sodium silicate aluminate were mixed to prepare a tablet with a tablet press.

Example 5 Investigation of Total Cholesterol Reduction Effect in Humans

  Eleven women aged 30 to 55 years were taken as a mixed powder tablet prepared as in Example 4, two tablets three times a day for two months, and then blood was collected before and after the administration to examine the total cholesterol content in the blood.

  As shown in Table 3, the total cholesterol content was decreased in all cases except the lowest RMH. Especially, KHS, which showed high cholesterol content before taking, showed a significant decrease of 30% in total cholesterol after 2 months. . The normal baseline was 110-240mg / dl, and most cholesterol levels were significantly decreased in the normal level. In the case of LHR, the cholesterol level decreased by 34%. This result shows that the mixed powder has a high cardiovascular disease improvement effect by reducing total cholesterol.

   <Table 3> Changes in Total Cholesterol Content in Blood

                      (Unit: mg / dl)

Before taking After taking KJS 194 174 JKJ 232 196 KJM 211 204 KDS 266 260 KSO 197 157 LHR 187 125 LYM 202 177 RMH 136 148 KHS 248 178 KSY 174 139 PJR 235 164

Example 6 Investigation of LDL Cholesterol Reduction Effect in Human

 After taking the same method as in Example 6, the blood was collected before and after taking the blood LDL cholesterol content was investigated.

 As shown in Table 4, the LDL cholesterol changes significantly decreased in all cases. Given that LDL cholesterol is between 65 and 160 mg / dl, the standard value is 2 months for JKJ, KDS and KHS. After a significant decrease to 91mg / dl, 160mg / dl, 107mg / dl, respectively, showed a normal range. In particular, LHR showed 45%, JKJ 43%, KHS 36%, and PJR 35%. This result shows that the mixed powder has a high cardiovascular disease improvement effect by reducing LDL cholesterol.

  <Table 4> Changes in LDL cholesterol content in blood

                      (Unit: mg / dl)

Before taking After taking KJS 114 96 JKJ 160 91 KJM 130 117 KDS 184 160 KSO 122 82 LHR 119 66 LYM 128 97 RMH 70 65 KHS 168 107 KSY 102 64 PJR 150 97

Example 7 Investigation of HDL Cholesterol Change in Humans

  After taking the same method as in Example 6, the blood was collected before and after taking the blood HDL cholesterol content was investigated.

  As shown in Table 5, most of the changes in HDL cholesterol were slightly increased or decreased within the normal range. For HDL, more than 40 mg / dl is the norm. HDL is responsible for degrading cholesterol, so the higher the normal value, the better the general result. After 2 months of JKJ, the HDL increased by 26% within the normal range.

  Through the above results, it can be seen that the mixed powder has a high cardiovascular disease improvement effect.

 <Table 5> Changes in HDL Cholesterol Content in Blood

                       (Unit: mg / dl)

Before taking After taking KJS 55 58 JKJ 57 72 KJM 59 51 KDS 56 51 KSO 53 65 LHR 57 50 LYM 58 53 RMH 54 61 KHS 57 61 KSY 56 51 PJR 54 52

Example 8 Hard Capsule Preparation

98% by weight of the mixed powder of Example 1 and 1% by weight of silicon dioxide were mixed to mix sodium silicate alumina to prepare a hard capsule with a capsule maker.

Example 9 Preparation of Granules

60 mesh granules were prepared by mixing 70 wt% of the mixed powder prepared in Example 1, 20 wt% of dextrin, and 10 wt% of glucose.

Example 10 Preparation of Pills

70% by weight of the mixed powder prepared in Example 1 and 30% by weight of the sulfuric acid powder were mixed to prepare a pill using a refiller.

Example 11 Reproduction

25% by weight of the mixed powder prepared in Example 1, 13% by weight of alpha brown powder, 11% by weight of oligosaccharide powder, 10% by weight of potato fiber fiber powder, 10% by weight of bran powder, 5.5% by weight of germ powder, barley sprout powder 5.2 Wt.%, Alpha barley germinated brown rice powder 3.7 wt%, glutinous rice brown rice powder 3.1 wt%, sweet potato powder 3 wt%, kale powder 2.4 wt%, potato powder 2.3 wt%, chestnut powder 1.7 wt%, pumpkin powder 1.5 wt%, stevia powder Reproduction was prepared by mixing 1.5% by weight, mugwort powder 0.8% by weight, and 0.3% by weight of radish powder.

Claims (4)

The present invention is a food additive composition characterized in that after the hot water, brown root, the deficiency extracted with hot water at 90 ~ 100 ℃, green tea extract, soybean powder. The food additive composition according to claim 1, wherein the weight ratios of Astragalus, green tea, brown root, soybean, and Cultivator extract are 0.1-10: 10, 0.1-10: 10, 0.1-10: 10, 0.1-10: 10, 0.1-10, respectively. Food having the effect of reducing cholesterol and improving cardiovascular disease, characterized by containing 5 to 100% by weight of the food additive composition according to claim 1 and 2. According to claim 3, wherein the food is a tablet, capsules, granules, pills, foods having an effect of reducing cholesterol and cardiovascular disease, characterized in that selected from raw or liquid formulations